-
Oppenheimer assumes Tarsus Pharmaceuticals (TARS) at Outperform (correction)
-
H.C. Wainwright Starts Tarsus Pharmaceuticals (TARS) at Buy
-
Elanco Animal Health (ELAN) sells certain royalties and commercial milestones associated with XDEMVY to Blackstone Life Sciences and Blackstone Credit & Insurance for $295M Cash
-
Tarsus Pharmaceuticals (TARS) Announces Proposed $100M Public Offering
-
Tarsus Pharmaceuticals (TARS) PT Raised to $58 at Jefferies
-
Tarsus Pharmaceuticals (TARS) PT Raised to $78 at Guggenheim
-
H.C. Wainwright Reiterates Buy Rating on Tarsus Pharmaceuticals (TARS)
-
Tarsus Pharmaceuticals, Inc. (TARS) Tops Q4 EPS by 17c
-
Tarsus Pharmaceuticals (TARS) PT Raised to $72 at Oppenheimer
-
Goldman Sachs Reiterates Neutral Rating on Tarsus Pharmaceuticals (TARS)
-
Tarsus Pharmaceuticals (TARS) Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
-
Guggenheim Reiterates Buy Rating on Tarsus Pharmaceuticals (TARS)
-
Tarsus Pharmaceuticals (TARS) PT Raised to $73 at H.C. Wainwright
-
Tarsus Pharmaceuticals, Inc. (TARS) Tops Q3 EPS by 33c
-
Tarsus Pharmaceuticals (TARS) Appoints Kate Goodrich to its Board
-
Tarsus Pharmaceuticals (TARS) Appoints Elizabeth Yeu as Chief Medical Officer
-
Oppenheimer Reiterates Outperform Rating on Tarsus Pharmaceuticals (TARS)
-
Guggenheim Reiterates Buy Rating on Tarsus Pharmaceuticals (TARS)
-
Guggenheim Reiterates Buy Rating on Tarsus Pharmaceuticals (TARS)
-
Oppenheimer Reiterates Outperform Rating on Tarsus Pharmaceuticals (TARS)
-
Tarsus Pharmaceuticals, Inc. (TARS) Tops Q2 EPS by 4c
-
4 small and mid-cap biopharma stocks to own according to BofA

